Ann: Virax secures $3 million placement , page-4

"..,this raising may act as a cap or lid..."

Agree, Strauss. I've also sold though I retain some in case VHL issues a positive IP statement and Novartis exercises its option over TG 4010.

If I'm still a holder come May 1, I will vote against the Pathway Oncology deal.

If enough join me, the deal won't go ahead.

Nor will the placement.

And nor will the material dilution.

The SP will rise.

As for GGTI-2418, I'm still awaiting an explanation from VHL as to why the Phase 1 trial of the drug was terminated under the auspices of Professor Peter O'Dwyer of the University of Pennsylvania.